Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Type 1 diabetes
FollowWhat is new in Type 1 diabetes research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Aspirin tabletPhase 3 · NCT06082063
- BaricitinibPhase 3 · NCT07222137 · NCT07222332
- Biological/VaccinePhase 3 · NCT06832410
- Cadisegliatin 800 mg BIDPhase 3 · NCT06334133
- Cadisegliatin 800 mg QDPhase 3 · NCT06334133 · NCT07616206
- CagrisemaPhase 3 · NCT07564414
- Dapagliflozin 10mg TabPhase 3 · NCT07056699
- Dapagliflozin 5mgPhase 3 · NCT04333823
- Dimethyl Fumarate Enteric-coated CapsulesPhase 3 · NCT07548996 · NCT07258394
- Dual Continuous Glucose and Ketone MonitorPhase 3 · NCT07211802
- FenofibratePhase 3 · NCT04929379 · NCT01320345
- FinerenonePhase 3 · NCT07594145 · NCT06082063
- Inert lactose placeboPhase 3 · NCT01320345
- Insulin aspartPhase 3 · NCT07076199
- Insulin glarginePhase 3 · NCT07076199
- Insulin glargine U-100Phase 3 · NCT07797335
- Insulin icodecPhase 3 · NCT07076199
- Intervention Period 1: Semaglutide + EmpagliflozinPhase 3 · NCT06894784
- Intervention Period 2: Semaglutide + Empagliflozin PlaceboPhase 3 · NCT06894784
- Intervention Period 3: Semaglutide Placebo + EmpagliflozinPhase 3 · NCT06894784
- Intervention Period 4: Semaglutide Placebo + Empagliflozin PlaceboPhase 3 · NCT06894784
- Islets of Langerhans transplantationPhase 3 · NCT00679042
- LenbelintidePhase 3 · NCT07776509 · NCT07784725
- Matching placebo capsulesPhase 3 · NCT07258394
- MetforminPhase 3 · NCT04583462 · NCT05414409
- OrforglipronPhase 3 · NCT06972459
- ORMD-0801 16 mgPhase 3 · NCT06731075
- ORMD-0801 8 mgPhase 3 · NCT06731075
- Pioglitazone 15 MG and 30mgPhase 3 · NCT07056699
- SAB-142Phase 3 · NCT07670650
- SemaglutidePhase 3 · NCT06082063 · NCT06982859 · NCT05822609 · NCT07564414 · NCT03899402 · NCT07087795 · NCT07891156 · NCT07430332
- Semaglutide 2.4mgPhase 3 · NCT06909006
- Semaglutide Pen InjectorPhase 3 · NCT05819138 · NCT06411210
- Semaglutide placeboPhase 3 · NCT06909006
- SotagliflozinPhase 3 · NCT06147232 · NCT05696366 · NCT07594145 · NCT06082063 · NCT06217302 · NCT06435156
- Sotagliflozin High DosePhase 3 · NCT07211802
- Sotagliflozin Low DosePhase 3 · NCT07211802
- Stem Cell Educator therapyPhase 3 · NCT04011020
- TeplizumabPhase 3 · NCT07610213 · NCT07088068 · NCT06791291 · NCT07216391
- TirzepatidePhase 3 · NCT05822544 · NCT06700538 · NCT06180616 · NCT07803744 · NCT07284511 · NCT06630585 · NCT06962280 · NCT06914895
- VK2735Phase 3 · NCT07868835 · NCT07104500
- VX-017Phase 3 · NCT04786262
- VX-880Phase 3 · NCT04786262
- ZenagamtidePhase 3 · NCT07797335
- blood samplingPhase 2/3 · NCT07880769
- DapagliflozinPhase 2/3 · NCT03899402
- InsulinPhase 2/3 · NCT07548996 · NCT06111586 · NCT03899402 · NCT03241706
- Insulin producing stem cells infusionPhase 2/3 · NCT06951074
- Professional CGMPhase 2/3 · NCT05219409
- Semaglutide (Wegovy) weekly injectionPhase 2/3 · NCT07797036
- Semaglutide with 4 meal strategiesPhase 2/3 · NCT06387199
- SitagliptinPhase 2/3 · NCT05219409
- Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM)Phase 2/3 · NCT07284511
- UstekinumabPhase 2/3 · NCT03941132
- Verapamil 120 Mg/24 Hours Oral Capsule, Extended ReleasePhase 2/3 · NCT07880769
- Verapamil oralPhase 2/3 · NCT07804849
- AbataceptPhase 2 · NCT03929601
- Abrocitinib 200 MG Oral TabletPhase 2 · NCT05743244
- AcetazolamidePhase 2 · NCT06981234
- Allogenic Human Islet CellsPhase 2 · NCT01909245 · NCT03746769
- Allogenic islet cells (human, U. Chicago)Phase 2 · NCT00160732 · NCT01241864
- AMX0035Phase 2 · NCT07699380
- Anti-CD20 (rituximab)Phase 2 · NCT06688331
- Anti-thymocyte globulin (ATG)Phase 2 · NCT07061574 · NCT06455319
- Antithymocyte Globulin (ATG)Phase 2 · NCT07216391
- Bacillus Calmette-GuérinPhase 2 · NCT02081326 · NCT05180591 · NCT05866536
- Basal insulinPhase 2 · NCT07224321
- BrivekimigPhase 2 · NCT06812988
- CIR-0602KPhase 2 · NCT07186660
- Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeksPhase 2 · NCT07247734
- Colchicine 0.5 MG Oral TabletPhase 2 · NCT05949281
- Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeksPhase 2 · NCT07247734
- CyclosporinPhase 2 · NCT05153070
- Dapagliflozin (Forxiga®)Phase 2 · NCT06072326
- Dapagliflozin 10 MGPhase 2 · NCT05938712
- DEXCOM G6Phase 2 · NCT06474598
- DFMOPhase 2 · NCT05594563
- DiamydPhase 2 · NCT05683990
- DulaglutidePhase 2 · NCT05478707 · NCT07319286
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)Phase 2 · NCT06688331
- FORXIGAPhase 2 · NCT07225465
- freezedried autologous encapsulated fecal microbiota transplantationPhase 2 · NCT07083882
- FrexalimabPhase 2 · NCT06111586
- Gastrin 17Phase 2 · NCT01909245 · NCT03746769
- GolimumabPhase 2 · NCT07683026
- High Dose SAB-142Phase 2 · NCT07187531
- ILT101Phase 2 · NCT05153070
- Immunosuppressive AgentsPhase 2 · NCT01909245
- Intraportal infusion of islet cellsPhase 2 · NCT00160732 · NCT01241864
- IvarmacitinibPhase 2 · NCT07845955
- IxekizumabPhase 2 · NCT04589325
- Liraglutide Pen InjectorPhase 2 · NCT06976619
- LisdexamfetaminePhase 2 · NCT05957055
- Low Dose SAB-142Phase 2 · NCT07187531
- MethylphenidatePhase 2 · NCT05957055
- MetoclopramidePhase 2 · NCT03970720
- MTX228Phase 2 · NCT06474598
- OPT101Phase 2 · NCT06964087
- Platelet Rich PlasmaPhase 2 · NCT06810726
- PS1Phase 2 · NCT07889505
- Recombinant Zoster Vaccine (Shingrix; RZV)Phase 2 · NCT07614412
- REMD-477Phase 2 · NCT04779645
- RezpegaldesleukinPhase 2 · NCT07142252
- RitlecitinibPhase 2 · NCT05743244
- rituximabPhase 2 · NCT07041268
- Rituximab-pvvrPhase 2 · NCT03929601
- Saline injectionPhase 2 · NCT02081326 · NCT05180591 · NCT05866536
- SC0062 and dapagliflozinPhase 2 · NCT06072326
- SC0062 strength 10mgPhase 2 · NCT06072326
- Semaglutide (Ozempic®)Phase 2 · NCT07614412
- Semaglutide, 1.0 mg/mLPhase 2 · NCT05938712
- SGLT-2 inhibitor (Sotagliflozin)Phase 2 · NCT07421518
- SorafenibPhase 2 · NCT06227221
- Sotagliflozin initiationPhase 2 · NCT07325201
- Sterile Sodium ChloridePhase 2 · NCT03929601
- Technosphere InsulinPhase 2 · NCT07224321
- Tirzepatide 2.5mg weeklyPhase 2 · NCT06820281
- verapamil extended release capsulePhase 2 · NCT06455319
- ZT-01, 15 mgPhase 2 · NCT05762107
- ZT-01, 22 mgPhase 2 · NCT05762107
- ZT-01, 7 mgPhase 2 · NCT05762107
- AdalimumabPhase 1/2 · NCT07061574
- Allogeneic Human E-islet (E-islet 01)Phase 1/2 · NCT07126873
- Allogeneic pancreatic endocrine cell clustersPhase 1/2 · NCT07581197
- ALN-4324Phase 1/2 · NCT06845202
- Arginine hydrochloridePhase 1/2 · NCT07167693
- ARO-ALK7Phase 1/2 · NCT06937203
- ARO-INHBEPhase 1/2 · NCT06700538
- Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNAPhase 1/2 · NCT06938334
- Beta-Air device for encapsulation of transplanted human isletsPhase 1/2 · NCT02064309
- CELZ-201 AdministrationPhase 1/2 · NCT05626712
- CNP-103Phase 1/2 · NCT06783309
- DenosumabPhase 1/2 · NCT06524960
- Human Pancreatic Islet TransplantationPhase 1/2 · NCT02846571
- Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapyPhase 1/2 · NCT06305286
- OPF-310Phase 1/2 · NCT06575426
- PAL-119Phase 1/2 · NCT07901595
- Sernova Cell PouchPhase 1/2 · NCT03513939
- Sodium Chloride 0.9%Phase 1/2 · NCT07167693
- the ATMP ProtransPhase 1/2 · NCT05061030
- Verapamil (Part A)Phase 1/2 · NCT07199946
- verapamil extended-release capsulePhase 1/2 · NCT07061574
- VolagidemabPhase 1/2 · NCT05696366
- VV-14299Phase 1/2 · NCT07829302
- VV-14300Phase 1/2 · NCT07829302 · NCT07831798
- VX-264Phase 1/2 · NCT05791201
- AcetaminophenPhase 1 · NCT07803744
- ACI-19764 at dose A1Phase 1 · NCT07463196
- ACI-19764 at dose A2Phase 1 · NCT07463196
- ACI-19764 at dose A3Phase 1 · NCT07463196
- ACI-19764 at dose A4Phase 1 · NCT07463196
- ACI-19764 at dose A5Phase 1 · NCT07463196
- ACI-19764 at dose A6Phase 1 · NCT07463196
- ACI-19764 at dose B1Phase 1 · NCT07463196
- ACI-19764 at dose B2Phase 1 · NCT07463196
- ACI-19764 at dose B3Phase 1 · NCT07463196
- ACI-19764 at dose C1Phase 1 · NCT07463196
- AMG 127Phase 1 · NCT07590193
- Aminohippurate Sodium 20 % InjectionPhase 1 · NCT05065372
- ATB-1011Phase 1 · NCT07590466
- ATB-1012Phase 1 · NCT07590466
- ATB-U101Phase 1 · NCT07590466
- ATB-U1011Phase 1 · NCT07590466
- ATB-U1012Phase 1 · NCT07590466
- BLX-7006Phase 1 · NCT07140055
- Degludec IVPhase 1 · NCT06945406
- Degludec SCPhase 1 · NCT06945406
- Dextrose solutionPhase 1 · NCT03241706
- Drug Metabolizing EnzymePhase 1 · NCT05822544
- DWC202502Phase 1 · NCT07539415
- DWC202503Phase 1 · NCT07539415
- DWRX5003Phase 1 · NCT07539415
- Efsubaglutide Alfa InjectionPhase 1 · NCT07518121
- ENC-201-CED hPIPhase 1 · NCT06408311
- ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo.Phase 1 · NCT07680673
- Ex vivo Expanded Human Autologous Regulatory T CellsPhase 1 · NCT06708780
- GL0034Phase 1 · NCT07385547
- GlucagonPhase 1 · NCT03241706
- GNTI-122Phase 1 · NCT06919354
- GS-4571Phase 1 · NCT06562907
- GZR-33Phase 1 · NCT07242664
- High FructosePhase 1 · NCT03241706
- HMS1005Phase 1 · NCT07568678
- Humulin R U-500Phase 1 · NCT07341373
- Hyperinsulinemic-euglycemic clampPhase 1 · NCT06105931
- IMC-S118AIPhase 1 · NCT07493122
- Infusion of concomitant Donor Derived Vertebral Bone MarrowPhase 1 · NCT05973734
- Infusion of recipient T regulatory cellPhase 1 · NCT05973734
- Intralymphatic Insulin Immunotherapy (ILIT)Phase 1 · NCT07610213
- Iohexol 300 Mg/mL Injectable SolutionPhase 1 · NCT05065372
- Islet cell transplantationPhase 1 · NCT00706420
- Islet Transplantation + ImmunosuppressionPhase 1 · NCT00706420
- Lispro SCPhase 1 · NCT06945406
- Low FructosePhase 1 · NCT03241706
- LY4057996 IVPhase 1 · NCT06945406
- LY4057996 SCPhase 1 · NCT06945406
- LY4167586Phase 1 · NCT07881887
- Lyumjev U-100 InsulinPhase 1 · NCT07341373
- Maridebart cafraglutidePhase 1 · NCT07160257
- Matching placeboPhase 1 · NCT07568678
- Mesenchymal Stem Cells (MSCs)Phase 1 · NCT04061746
- Metformin Hcl 1000Mg TabPhase 1 · NCT05065372
- MS-553Phase 1 · NCT04187443
- MTX-101Phase 1 · NCT06324604
- MWN105 1Phase 1 · NCT07803809
- MWN105 2Phase 1 · NCT07803809
- MWN105 3Phase 1 · NCT07803809
- NNC0194-0499Phase 1 · NCT07087795
- NNC0497-0040Phase 1 · NCT07578584
- NNC1679-0001Phase 1 · NCT07570992
- NNC9836-0001Phase 1 · NCT07896109
- OmeprazolePhase 1 · NCT06562907
- Only PRP injectionPhase 1 · NCT05610865
- oral insulinPhase 1 · NCT07634770
- Portal Insulin U-500Phase 1 · NCT07341373
- Pre-study basal insulin SCPhase 1 · NCT06945406
- PRP + ASCs injectionPhase 1 · NCT05610865
- PRP + SVF injectionPhase 1 · NCT05610865
- RetatrutidePhase 1 · NCT06982859
- RGB-5088Phase 1 · NCT06731218
- SalinePhase 1 · NCT03241706
- SomatostatinPhase 1 · NCT03241706
- subcutaneous insulinPhase 1 · NCT07634770
- TIX100Phase 1 · NCT07675590
- TLC-6740 Oral SolutionPhase 1 · NCT05822544
- TLC-6740 TabletPhase 1 · NCT05822544
- Tolerogenic Dendritic Cell VaccinePhase 1 · NCT04590872
- Allogeneic CD7-Targeted CAR-T Cell InjectionEarly phase 1 · NCT07528105
- Aspirin 80 mg EC TabEarly phase 1 · NCT05105919
- AutoCD6-CAR Treg cellsEarly phase 1 · NCT07395050
- C-peptideEarly phase 1 · NCT06470295
- CARC-101CEarly phase 1 · NCT06546436
- CRG002Early phase 1 · NCT07503028
- DHEAEarly phase 1 · NCT03228732
- DichloroacetateEarly phase 1 · NCT05317455
- DPP System (Insulin Pump and Continuous Glucose Monitoring Platform)Early phase 1 · NCT07655076
- ECP accelerated-intensity armEarly phase 1 · NCT05413005
- ECP regular-intensity armEarly phase 1 · NCT05413005
- FluoxetineEarly phase 1 · NCT03228732
- Fluoxetine and DHEAEarly phase 1 · NCT03228732
- RD13-02 cell infusionEarly phase 1 · NCT07142161
- ResveratrolEarly phase 1 · NCT04449198
- Semaglutide (Rybelsus®)Early phase 1 · NCT06338553
- Sodium Glucose Co-transporter 2 (SGLT2) InhibitorEarly phase 1 · NCT06609356
- Study Visit 1Early phase 1 · NCT06609356
- Study Visit 2Early phase 1 · NCT06609356
- T1DM standard of careEarly phase 1 · NCT05413005
- UP421Early phase 1 · NCT06239636
Closest to patients
- Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolIslet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolCellTrans Inc. (sponsor) · 1 hospital in United StatesPhase 3Primary completion 2017
- Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration TrialAdolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration TrialThe Hospital for Sick Children · Toronto, Canada + 2 more hospitalsPhase 3Primary completion 2024
- Effects of Sitagliptin in Relatives of T1D PatientsEffects of Sitagliptin in Relatives of T1D PatientsASST FBF Sacco · Milan, ItalyPhase 2/3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Functional restoration of disease-associated VDR-CH variants through heterodimeric partner RXR and VDR ligand calcitriol partnership.
Functional restoration of disease-associated VDR-CH variants through heterodimeric partner RXR and VDR ligand calcitriol partnership.
Cellular signalling
PubMed · PMID 42977204Publication
Prevalence, Diagnostic Role, and Clinical Features of Zinc Transporter 8 Autoantibody in Korean Children and Adolescents With Diabetes Mellitus.
Prevalence, Diagnostic Role, and Clinical Features of Zinc Transporter 8 Autoantibody in Korean Children and Adolescents With Diabetes Mellitus.
Journal of Korean medical science
PubMed · PMID 42936974Publication
Timing of Insulin Glargine Administration During Intermittent Ramadan Fasting in patients With Type1 Diabetes: A Randomized Controlled Trial (GLARIF).
Timing of Insulin Glargine Administration During Intermittent Ramadan Fasting in patients With Type1 Diabetes: A Randomized Controlled Trial (GLARIF).
Journal of diabetes science and technology
PubMed · PMID 42891564Publication
Metabolic outcomes and insulin therapy modifications during Ramadan fasting in children with type 1 diabetes mellitus in low-resource settings.
Metabolic outcomes and insulin therapy modifications during Ramadan fasting in children with type 1 diabetes mellitus in low-resource settings.
Pediatric endocrinology, diabetes, and metabolism
PubMed · PMID 42902702
Find fellow researchers
Groups with active Type 1 diabetes work.
University of Copenhagen
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
University of Colorado Anschutz
Aurora, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Brigham and Women's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford University
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Steno Diabetes Center Copenhagen
Herlev, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
University of Washington
Seattle, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it